Latest Blog Posts Tagged "Industry"
October 25, 2018
'Forbes' published a story detailing a 'milestone moment' in the history of LRRK2 and role of the Foundation in ushering this promising genetic target forward.
October 24, 2018
Cerevel Therapeutics gains preclinical and clinical-stage drugs from Pfizer's previous neuroscience program.
October 23, 2018
The Phase II trial is recruiting people with PD ages 40 to 80 to test a drug that targets alpha-synuclein.
June 04, 2018
A drug trial for people with a genetic form of Parkinson's disease (PD) is recruiting volunteers at more than 30 sites around the world.
March 19, 2018
Acquisitions can bring experience and funds to move Parkinson's therapies through testing and to patient hands faster.
October 03, 2016
Dale B. Schenk, PhD, a leader in the movement to treat neurodegenerative diseases with antibodies, died September 30.
August 14, 2015
Neuropore Therapies and Biogen grow the field of clinical trials with approaches against alpha-synuclein, our most promising target for a therapy to slow or stop Parkinson's progression.
July 29, 2015
Drugs in development that go after the processes, rather than the proteins, involved in Alzheimer's onset may have potential to treat Parkinson's disease, as well.
July 21, 2015
Pfizer video highlights collaboration with The Michael J. Fox Foundation.
February 04, 2015
The Foundation has united three powerhouse pharmaceutical companies for a pre-competitive consortium to advance LRRK2 inhibitors as potential disease-modifying medications.